-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 20, 2021, Delfi Diagnostics announced that the company's new early blood screening technology based on machine learning has achieved positive results in a prospective study to help improve early lung cancer detection
.
The results show that this new type of lung cancer screening technology, by using advanced machine learning algorithms to analyze the genome fragmentation map of cell-free DNA (cfDNA), can accurately detect in a group of individuals undergoing low-dose CT (LDCT) scans Approximately 90% of cancer cases
Lung cancer is one of the leading causes of cancer deaths worldwide
.
The vast majority of lung cancers are already at an advanced stage where the prognosis is often poor when they are diagnosed
Usually, liquid biopsy detects the signs of cancer by detecting genetic mutations or DNA methylation changes in DNA fragments in the blood
.
Delfi's liquid biopsy takes another approach, using advanced machine learning technology to analyze the genome fragmentation characteristics of cell-free DNA in the whole genome
▲Delfi's liquid biopsy diagram (picture source: Delfi's official website)
The prospective study called "LUCAS" enrolled 365 subjects over a 7-year period, most of whom had a high risk of lung cancer and smoking-related symptoms, such as coughing or dyspnea
.
The results of this study were verified in another study involving 431 subjects (with or without lung cancer)
When Delfi's liquid biopsy is used as an early screening method to determine whether patients need LDCT scans, the combination of the two detects 90% of lung cancer patients, including 80% of stage I lung cancers, and the number of unnecessary LDCTs Reduce by 50%
.
"Because blood testing is much easier than LDCT, we believe that a high-performance, cost-effective testing method can greatly increase the number of early detection of lung cancer, thereby improving treatment results
.
Compared with the current standard of care, it can also eliminate a lot of “The false positive result of the
Reference materials:
[1] Mathios, D.
[2] Delfi Liquid Biopsy Shows Promise for Reducing Lung Cancer Deaths.
